

Evolution Cost and usage (biosimilar)biologicals The Netherlands 2014-2018 GIP-database								
24-11-2019								
GIP-databank								
https://www.gipdatabank.nl/databank#/g/00-totaal/R_04_addon/vg								
	year	2014	2015	2016	2017	2018	change over 2014-2018	% change since 2014
							5 years	5 years
Adalimumab								
expenditure (million euros)								
L04AB04	Adalimumab	224.559	220.014	215.955	215.555	210.054	-14.505	-6,5%
number of users								
L04AB04	Adalimumab	18.576	19.227	19.763	20.678	21.532	2.956	15,9%
expenditure per user (euros)								
L04AB04	Adalimumab	12.089	11.443	10.927	10.424	9.755	-2.334	-19,3%
Etanercept								
expenditure (million euros)								
L04AB01	Etanercept	155.943	148.397	142.940	125.763	101.241	-€ 54.702	-35,1%
number of users								
L04AB01	Etanercept	14.265	14.695	15.469	16.035	16.506	2.241	15,7%
expenditure per user (euros)								
L04AB01	Etanercept	10.932	10.098	9.240	7.843	6.134	-€ 4.798	-43,9%
Infliximab								
expenditure (million euros)								
L04AB02	Infliximab	154.485	154.584	139.574	107.733	99.946	-€ 54.539	-35,3%
number of users								
L04AB02	Infliximab	10.015	10.717	11.578	12.209	12.983	2.968	29,6%
expenditure per user (euros)								
L04AB02	Infliximab	15.425	14.424	12.055	8.824	7.698	-€ 7.727	-50,1%
Certolizumab-pegol								
expenditure (million euros)								
L04AB05	Certolizumab	6.486	8.695	9.937	11.161	12.009	€ 5.523	85,2%
number of users								
L04AB05	Certolizumab	693	976	1.157	1.345	1.575	882	127,3%
expenditure per user (euros)								
L04AB05	Certolizumab	9.359	8.909	8.589	8.298	7.625	-€ 1.734	-18,5%
Golimumab								
expenditure (million euros)								
L04AB06	Golimumab	23.453	23.478	23.305	20.522	19.566	-€ 3.887	-16,6%
number of users								
L04AB06	Golimumab	2.067	2.065	2.071	1.996	1.982	-85	-4,1%
expenditure per user (euros)								
L04AB06	Golimumab	11.346	11.370	11.253	10.282	9.872	-€ 1.474	-13,0%

Rituximab								
Expenditure (million euros)								
L01XC02	Rituximab	62.237	61.685	62.470	63.825	44.610	-17.627	-28,3%
number of users								
L01XC02	Rituximab	7.112	7.022	7.371	8.455	9.050	1.938	27,2%
expenditure per user (euros)								
L01XC02	Rituximab	€ 8.751	€ 8.784	€ 8.475	€ 7.549	€ 4.929	-€ 3.822	-43,7%
Trastuzumab								
Expenditure (million euros)								
L01XC03	Trastuzumab	79.698	77.695	77.349	74.007	69.886	-€ 9.812	-12,3%
number of users								
L01XC03	Trastuzumab	4.179	4.297	4.294	4.389	4.624	445	10,6%
expenditure per user (euros)								
L01XC03	Trastuzumab	19.071	18.081	18.013	16.862	15.114	-€ 3.957	-20,7%
Bevacizumab data not reliable; combination of systemic / ocular since 2017)								
Expenditure (million euros)								
L01XC07	Bevacizumab	49.621	55.191	57.785	54.303	55.599	€ 5.978	12,0%
number of users								
L01XC07	Bevacizumab	3.822	4.007	3.965	33.893	39.501	35.679	933,5%
expenditure per user (euros)								
L01XC07	Bevacizumab	12.983	13.774	14.574	1.602	1.408	-€ 11.575	-89,2%